SERES GuruFocus.com / Apr 28, 2022
GuruFocus Article or News written by Business Wire and the topic is about:
Seres Therapeutics to Host Fir
GuruFocus.com
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
SERES News
SERES Ripon College Days / Apr 27, 2022
Analyst Rating: Will Seres Therapeutics Inc (MCRB) Stock Do Better Than the Market?
SERES Ripon College Days / Apr 27, 2022
New Jersey, United States - The Human Micobiome Market research report offers co
SERES Ripon College Days / Apr 27, 2022
New Jersey, United States - The study is a professional and comprehensive assessment of the Onl
SERES themobility.club / Apr 25, 2022
MarketsandResearch.biz led the statistical surveying on Global Human Microbiome Market considering a
SERES CleanTechnica / Apr 24, 2022
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
SERES CleanTechnica / Apr 24, 2022
China Edition Plugin vehicles are all the rage in the Chinese auto market. Even with Covid-related lockdowns happening in some major cities, plugins scored 458,000 registrations, up 118% year over year
CleanTechnica
SERES SURPERFORMANCE / May 8, 2021
Seres Therapeutics, Inc. (NASDAQ:MCRB) - Investment analysts at Oppenheimer issued their Q2 2022 earnings estimates for Seres Therapeutics in a research report issued to clients and investors on Tuesday, May 4th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will earn
SURPERFORMANCE
SERES SURPERFORMANCE / May 8, 2021
Item 1.01 Entry into a Material Definitive Agreement. First Amendment to the Agreement and Plan of Merger On May 7, 2021, Forum Merger III Corporation entered into an amendment to that certain... | May 8, 2021
SERES MarketBeat / May 5, 2021
Seres Therapeutics (NASDAQ:MCRB) had its target price increased by stock analysts at HC Wainwright from $41.00 to $46.00 in a report released on Wednesday, The Fly reports. The firm currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's price target points to a potential upside of 97.34% from the company's previous close.
MarketBeat
SERES Investing.com / May 5, 2021
11 hours ago (May 05, 2021 06:22AM ET) Canaccord Genuity analyst John Newman maintained a Buy rating on Seres Therapeutics (NASDAQ:) on Tuesday, setting a price target of $42, which is approximately 95.53% above the present share price of $21.48. Newman expects Seres Therapeutics to post earnings per share (EPS) of -$0.19 for the second quarter of 2021.
Investing.com
SERES InvestorsObserver / May 5, 2021
The 52 rating InvestorsObserver gives to Seres Therapeutics Inc ( MCRB) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 83 percent of stocks in the Biotechnology industry, MCRB's 52 overall rating means the stock scores better than 52 percent of all stocks.
SERES Paul Tan's Automotive News / May 5, 2021
Oppo, a smartphone and electronics subsidiary of BBK Electronics, is reportedly looking to enter the car business, following in the footsteps of companies like Huawei and Xiaomi. According to reports in China compiled by CarNewsChina, Tony Chen, the founder and CEO of Oppo, is heading the project and the company is in the midst hiring talent and exploring pathways.
Chinese smartphone brand Oppo wants to build a car
Paul Tan's Automotive News
SERES Explica / May 5, 2021
Do you remember when mobile phones came into our lives? It seems like a long time ago but no, it's only been two decades. The fact is that during the first years it was Nokia the one he dominated with an iron fist, until he "screwed up" by going against the current when Google created Android.
SERES Business Wire / May 4, 2021
CAMBRIDGE, Mass.--()-- Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported first quarter 2021 financial results and provided business updates.
SERES SFGate / May 4, 2021
CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Tuesday reported a loss of $35.5 million in its first quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 39 cents. The results did not meet Wall Street expectations.
SERES Nasdaq / May 4, 2021
Seres Therapeutics (MCRB) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.
SERES Yahoo Finance / May 4, 2021
NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Seres Therapeutics, Inc. (NASDAQ:MCRB) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 8:30 AM Eastern Time.
Seres Therapeutics, Inc. to Host Earnings Call
Yahoo Finance
SERES Yahoo Entertainment / May 4, 2021
Decenas de personas peregrinan por los hospitales de la capital mexicana a los que trasladaron a los heridos del accidente del metro en busca de sus familiares y amigos. Aquí el testimonio de un joven que busca con desesperación a su amiga embarazada.
SERES Equities.com / May 4, 2021
Seres Theraptc (NASDAQ: MCRB) shares gained 5.55% to end trading Tuesday at $21.48 per share - a net change of $1.13. Shares traded between $21.99 and $19.83 throughout the day. 1268954 shares of Seres Theraptc exchanged hands. Visit Seres Theraptc's profile for more information.
Seres Theraptc (MCRB) gains 5.55% for May 04
Equities.com